Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Progress in filovirus vaccine development: evaluating the potential for clinical use.

Falzarano D, Geisbert TW, Feldmann H.

Expert Rev Vaccines. 2011 Jan;10(1):63-77. doi: 10.1586/erv.10.152. Review.

2.

Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies.

Nakayama E, Yokoyama A, Miyamoto H, Igarashi M, Kishida N, Matsuno K, Marzi A, Feldmann H, Ito K, Saijo M, Takada A.

Clin Vaccine Immunol. 2010 Nov;17(11):1723-8. doi: 10.1128/CVI.00170-10. Epub 2010 Sep 22.

3.

Prospects for immunisation against Marburg and Ebola viruses.

Geisbert TW, Bausch DG, Feldmann H.

Rev Med Virol. 2010 Nov;20(6):344-57. doi: 10.1002/rmv.661. Review.

4.

Postexposure treatment of Marburg virus infection.

Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, Grolla A, Feldmann H.

Emerg Infect Dis. 2010 Jul;16(7):1119-22. doi: 10.3201/eid1607.100159.

5.

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.

Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan NJ.

PLoS Pathog. 2010 May 20;6(5):e1000904. doi: 10.1371/journal.ppat.1000904.

6.

Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.

Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, Holman DH, Dong JY.

Clin Vaccine Immunol. 2010 Apr;17(4):572-81. doi: 10.1128/CVI.00467-09. Epub 2010 Feb 24.

7.

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.

Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H.

J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.

8.

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Sullivan NJ, Martin JE, Graham BS, Nabel GJ.

Nat Rev Microbiol. 2009 May;7(5):393-400. doi: 10.1038/nrmicro2129. Review. Erratum in: Nat Rev Microbiol. 2009 Sep;7(9):684.

PMID:
19369954
9.

Experimental vaccine may have saved Hamburg scientist from Ebola fever.

Tuffs A.

BMJ. 2009 Mar 23;338:b1223. doi: 10.1136/bmj.b1223. No abstract available.

PMID:
19307268
10.

Disease modeling for Ebola and Marburg viruses.

Bente D, Gren J, Strong JE, Feldmann H.

Dis Model Mech. 2009 Jan-Feb;2(1-2):12-7. doi: 10.1242/dmm.000471.

11.

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.

Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, Paragas J, Matthias L, Smith MA, Jones SM, Hensley LE, Feldmann H, Jahrling PB.

PLoS Pathog. 2008 Nov;4(11):e1000225. doi: 10.1371/journal.ppat.1000225. Epub 2008 Nov 28.

12.

Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda.

Towner JS, Sealy TK, Khristova ML, Albariño CG, Conlan S, Reeder SA, Quan PL, Lipkin WI, Downing R, Tappero JW, Okware S, Lutwama J, Bakamutumaho B, Kayiwa J, Comer JA, Rollin PE, Ksiazek TG, Nichol ST.

PLoS Pathog. 2008 Nov;4(11):e1000212. doi: 10.1371/journal.ppat.1000212. Epub 2008 Nov 21.

13.

Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies.

Kuhn JH.

Arch Virol Suppl. 2008;20:13-360. Review. No abstract available.

PMID:
18637412
14.

Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.

Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, Hensley LE, Feldmann H, Jones SM.

J Virol. 2008 Jun;82(11):5664-8. doi: 10.1128/JVI.00456-08. Epub 2008 Apr 2.

15.

Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.

Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD.

Clin Vaccine Immunol. 2008 Mar;15(3):460-7. doi: 10.1128/CVI.00431-07. Epub 2008 Jan 23.

16.

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7.

PMID:
17940980
17.

In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein.

Ebihara H, Theriault S, Neumann G, Alimonti JB, Geisbert JB, Hensley LE, Groseth A, Jones SM, Geisbert TW, Kawaoka Y, Feldmann H.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S313-22.

PMID:
17940966
18.

Successful topical respiratory tract immunization of primates against Ebola virus.

Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A.

J Virol. 2007 Jun;81(12):6379-88. Epub 2007 Apr 11.

19.

Effective post-exposure treatment of Ebola infection.

Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, Hensley LE, Geisbert TW.

PLoS Pathog. 2007 Jan;3(1):e2.

20.

Molecular determinants of Ebola virus virulence in mice.

Ebihara H, Takada A, Kobasa D, Jones S, Neumann G, Theriault S, Bray M, Feldmann H, Kawaoka Y.

PLoS Pathog. 2006 Jul;2(7):e73.

Supplemental Content

Support Center